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Abstract
Mithramycin (MTM), a cytotoxic compound, is currently being investigated for its anti-angiogenic activity that seems to be
mediated through an inhibition of the transcription factor SP1. In this study we evaluated its anti-myeloma effects in the
syngenic 5TGM1 model in vitro as well as in vivo. In vitro, MTM inhibited DNA synthesis of 5TGM1 cells with an IC50 of
400 nM and induced an arrest in cell cycle progression at the G1/S transition point. Western-blot revealed an up-regulation
of p53, p21 and p27 and an inhibition of c-Myc, while SP1 remained unaffected. In rat aortic ring assays, a strong anti-
angiogenic effect was seen, which could be explained by a decrease of VEGF production and an up-regulation of anti-
angiogenic proteins such as IP10 after MTM treatment. The administration of MTM to mice injected with 5TGM1 decreased
5TGM1 cell invasion into bone marrow and myeloma neovascularisation. These data suggest that MTM displays anti-
myeloma and anti-angiogenic effects that are not mediated by an inhibition of SP1 but rather through c-Myc inhibition and
p53 activation.
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Introduction
Multiple myeloma (MM) is a haematological malignancy
affecting terminally differentiated B cells and characterized by
bone marrow (BM) infiltration by plasma cells secreting a
monoclonal paraprotein [1]. The disease is heterogeneous with a
wide range of clinical manifestations and differing outcomes that
are driven by its genetic and biological characteristics [2]. These
genetic alterations finally contribute to a malignant phenotype
with a capacity for self-renewal and a potential for a low rate of
proliferation, in contrast to normal plasma cells [3].
In addition to these genetic changes, an evolving crosstalk
between myeloma cells and other cell types within the BM
microenvironment can also account for MM development. This
crosstalk favours the activation of fibroblasts to secrete different
growth factors and of endothelial cells to initiate an angiogenic
response. Cells from the BM microenvironment also stimulate
immune and inflammatory cells and disrupt the balance between
osteoblasts and osteoclasts, leading to osteolysis [4]. Angiogenesis
in the BM also seems to play an important role in the pathogenesis
of MM [5]. Indeed, increased BM microvessel density (MVD) in
patients with MM has been correlated with disease progression
and poor prognosis [6]. Rajkumar et al. have shown a gradual
increase of BM angiogenesis along the disease spectrum from
monoclonal gammopathy of undetermined significance to smoul-
dering MM, newly diagnosed MM and relapsed MM [7].
However, gene expression studies showed that normal BM plasma
cells already express some pro-angiogenic genes and an accumu-
lation of normal plasma cells can already induce a basal level of
angiogenesis in the BM [8]. Aberrant expression of pro-angiogenic
genes (vascular endothelial growth factor [VEGF], basic fibroblast
growth factor [bFGF], and hepatocyte growth factor [HGF]), and
down-regulation of anti-angiogenic genes by MM cells further
increase the angiogenic stimulus and explains the presence of BM
angiogenesis at various degrees in all myeloma patients [5]. The
main problem in the development of anti-angiogenic agents is that
multiple angiogenic molecules may be produced by tumours, and
tumours at different stages of development may depend on
different angiogenic factors for their blood supply.
In the current study, we evaluated the anti-myeloma effects of
mithramycin (MTM), a natural polycyclic aromatic polyketide
produced by Streptomyces species [9]. MTM binds preferentially to
GC-rich sequences in DNA corresponding to transcription factor
SP (specific protein) binding sites, inhibits expression of SP-
regulated genes, and has anticancer activity [10–12]. Recently,
there has been a renewed interest in this compound because of its
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newly-described anti-angiogenic effects and the use of analogues
with distinct anti-cancer effects [12–15].
Materials and Methods
Cell Culture
The 5TGM1 myeloma cell line was subcloned from a stroma-
independent cell line originally established from the parent murine
5T33MM (IgG2bk) myeloma cell line [16,17], which arose
spontaneously in an aged C57BL/KaLwRij mouse [18]. This cell
line was kindly provided by G Mundy (Vanderbilt University,
Nashville, TN, USA). The 5TGM.1 model closely reflects different
aspects of the MM disease seen in humans. For example, it include
the growth of myeloma in bone, the dependency of the myeloma
on the bone microenvironment for its growth and survival, the
production of a paraprotein that reflects myeloma burden and the
associated osteolytic processes. The 5TGM1 murine myeloma cell
line was cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Invitrogen, Grand Island, NY, USA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS; Thermo Scientific,
Rockford, IL, USA), 100 U/ml penicillin–streptomycin, and
2 mM L-glutamine (Invitrogen). 5TGM1 cells have been genet-
ically engineered to stably express eGFP (5TGM1-eGFP cells)
[19]. For inoculation into mice, cultured cells were harvested and
resuspended in serum-free DMEM at a concentration of 2.5 105
cells/200 ml. The BM endothelial cell line STR-4 and STR-10
were kindly provided by Dr M Kobayashi and also cultured in
supplemented RPMI-1640 [20].
Reagents
MTM was purchased from Sigma-Aldrich (St. Louis, MO,
USA) and dissolved in DMSO to obtain a stock solution at
500 mM.
Proliferation Assay
In vitro proliferation and viability was assessed using MTT assay
according to the manufacturers recommendations (Cell Prolifer-
ation Kit I, MTT, Roche Diagnostics GmbH, Mannheim,
Germany). Cells were cultured for 24 h in DMEM medium (96-
well plates) supplemented with different concentrations of MTM
or with the vehicle alone used as control. This culture was followed
by a incubation with 10 mL MTT labelling reagent for 4 h at
37uC. Then 100 mL of solubilisation solution were added to each
well overnight at 37uC and absorbance at 560 nm was read on a
Microplate reader.
Apoptosis Assay
5TGM1 cells were cultured in 6-well plates at a density of
150,000 cells in 200 ml. Cells were incubated during 24 h with
MTM (0 nM, 200 nM, 400 nM, 800 nM and 1600 nM) and
harvested. Cells were incubated with FITC-annexin V and
propidium iodide (Annexin V: FITC Apoptosis Detection Kit I;
BD Biosciences, San Jose, CA, USA) according to the manufac-
turer’s instructions. Apoptosis was assessed by flow cytometry
using a FACS Canto II (BD Biosciences). The numbers indicate
percentage of cell population in each quadruplet. Lower left:
normal cells; lower right: apoptotic cells; upper right: late
apoptotic and necrotic cells.
Cell Cycle Analysis
5TGM1 cells were cultured in 6-well plates at a density of
150,000 cells in standard culture medium. After 24 h of incubation
with increasing concentrations of MTM (0 nM, 200 nM,
400 nM), cells were harvested, washed twice with PBS and fixed
in ethanol for 30 min at 4uC. After that, cells were stained with
propidium iodide (100 mM/ml in PBS, Sigma). Flow cytometry
was performed on a FACS Calibur (BD Biosciences) and the
percentage of cells in each phase of the cycle was calculated using
the Modfit software (Verity Software House, Topsham, ME,
USA).
Western Blot
After 24 h incubation with different concentrations of MTM,
cells were harvested and the cell pellets were washed with PBS.
Cells were then lysed in a buffer containing SDS 1%, a protease
inhibitor (Thermo Scientific) and a phosphatase inhibitor (phos-
STOP; Roche, Mannheim, Germany). Proteins were separated on
a 12% acrylamide gel under reducing conditions and transferred
to PVDF membranes (Bio-Rad, Hercules, CA, USA). Following
the transfer, membranes were blocked for 2 h with PBS containing
5% non-fat dried milk and 0.1% Tween 20 and incubated
overnight at 4uC with the appropriate primary antibody namely c-
Myc (9E10; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
SP1 (AnaSpec, Fremont, CA, USA), cyclin D1 (C-20; Santa Cruz
Biotechnology), p21 (C19; Santa Cruz Biotechnology), p27 (C19:
Santa Cruz Biotechnology), p53 (Millipore), cyclin B1 (GNS1;
Santa Cruz Biotechnology), cyclin E (M-20; Santa Cruz Biotech-
nology), cdk2 (M2; Santa Cruz Biotechnology), cdk4 (C-22; Santa
Cruz Biotechnology), cdk6 (C-21; Santa Cruz Biotechnology),
phospho Rb (Ser 780) (9307; Cell Signalling, Danvers, MA, USA).
Membranes were washed in PBS-Tween buffer and incubated
with the appropriate HRP-conjugated secondary antibody diluted
1:2000 in PBS containing 5% milk and 0.1% Tween-20. After
three washes, bands were visualised using the ECL plus system
(Perkin Elmer). B-actin (Sigma-Aldrich) was used as a loading
control.
Endothelial Cell Migration and Wound Healing Assay
For studying chemotaxis of STR-4 and STR-10 cells, uncoated
8-mm Nucleopore filters (Whatman, Middlesex, UK) were used in
48-well invasion chamber (Neuroprobe), as previously described
[21]. Cells were treated with 200 nM or 400 nM of MTM or
vehicle. Chambers were incubated at 37uC for 24 h and cell were
able to migrate. Migration was quantified by counting the number
of cells on the lower surface of the filters (30 random fields). Results
are expressed as mean number of migrating or invading cells per
30 fields 6 SE and are those of one representative experiment
done at least three time (each experimental condition done in
quadruplicates).
In the wound healing assay, STR-4 and STR-10 cells were
seeded at a density of 3.56104/mL and 4.16105/mL, respectively,
into sterile cell culture inserts (Ibidi GmBH, Munich, Germany).
Twenty-four hours after seeding, the cell culture insert was
carefully removed, revealing a defined 500-mm gap in the attached
cells. Cells were incubated with RPMI medium containng 10%
FBS and 200 nM and 400 nM Mithramycin. Endothelial cells
were monitored for migration into the wound using a phase
contrast microscopy (Zeiss Axiovert 25 microscope equipped with
an Axiocam Zeiss camera). Areas without cell were quantified
using the ImageJ program.
In vitro Angiogenesis: the Rat Aortic Ring Assay
Before the experiment, conditioned medium (3 ml per condi-
tion) was prepared by culturing 105 5TGM1 cells during 48 h in
DMEM supplemented with the vehicle solution or 200 nM or
400 nM of MTM. DMEM was mixed (1:1) with MCDB, a
classical medium used in aortic ring assays. DMEM+MCDB and
VEGF were used as negative and positive controls respectively.
Effects of Mithramycin on Myeloma and Angiogenesis
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The rat aortic ring assays were performed as previously described
[22]. A computarized method of quantification was used to
determine the mean microvessel distribution defined as the
number of vessels at various distances from the aortic ring. For
this, image processing was performed with the Aphelion 3.2
(Adcis) software and measurements with Matlab (7.9.0) software
(Mathworks, Natick, MA, USA), according the algorithm
described in Blacher et al. [23].
In vitro Angiogenesis: Spheroid Sprouting Assay
Multicellular spheroids were generated by seeding 15000 STR-
4 or STR10 cells in each well of non-adherent round-bottomed
96-well plates, in DMEM (Gibco BRL) containing 5% FBS and
0.24% high-viscosity methylcellulose (Sigma-Aldrich) [24]. After
24 hours of culture, spheroids were collected (maximum of eight
per well), embedded in collagen gels in 48-well plates, and
maintained in 2% FBS DMEM at 37uC for 24 hours.
Mithramycin was added at a final concentration of 200 nM or
400 nM. Cells were examined under a Zeiss Axiovert 25
microscope equipped with an Axiocam Zeiss camera and KS
400 Kontron image analysis software (Carl Zeiss Microscopy,
Zaventem, Belgium). Images were quantified as earlier described
[24].
In vivo Treatment with MTM on the 5TGM1 Mouse Model
C57BL/KaLwRij mice were purchased from Harlan (Horst,
Netherlands). Animals were housed under conventional conditions
and had free access to food and tap water. All procedures
involving these mice were approved by the local animal ethics
committee at the University of Lie`ge. For the in vivo experiment,
C57BL/KaLwRij mice (n = 20) were injected intravenously with
2.5 104 GFP-transfected 5TGM1 cells. Starting the day after
injection, one group of mice was treated intraperitonealy twice
weekly with MTM (0.750 mg/kg) while the second group was
treated with the vehicle (DMSO dissolved in PBS). When mice
showed first signs of paraplegia (at day 32), all animals were
sacrificed. BM was flushed from one tibia and one femur and BM
mononuclear cells were isolated by adding Red Blood cell lysis
buffer on the cell suspension (Sigma-Aldrich). Tumour load was
determined by flow cytometric analysis of GFP cells. The second
tibia and the second femur were fixed for immunohistochemical
staining. The bones were fixed by immersion for 48 h in zinc
fixative and immersed in a decalcification solution for 48 h. Spleen
weight was measured. CD31 staining was performed using
immunohistochemistry as described previously [25].
ELISA for VEGF and IP10
VEGF and interferon gamma-induced protein 10 (IP10) (R&D
Systems, USA) were measuredby ELISA on conditioned medium
from untreated cells and cells treated with 200 nM or 400 nM of
MTM for 24 h according to the manufacturer’s protocol. IP10
ELISA was also performed on lysates of treated and untreated
cells.
Angiogenesis Cytokine Array
Proteome Profiler Mouse Angiogenesis array (R&D Systems)
was performed on conditioned medium from untreated cells and
cells treated with 400 nM of MTM for 24 h according to the
manufacturer’s protocol.
Statistical Analysis
All experiments were performed in at least triplicates. Results
were expressed as score means 6 standard error of means (SEM).
Statistical analyses were performed by Student t-test using the
Instat software (GraphPad, La Jolla, CA, USA) (*p,0.05;
**p,0.01; ***p,0.001).
Results
In vitro Effects of MTM on 5TGM.1 Cell Proliferation and
Cell Cycle Progression
We initially assessed the effect of MTM on 5TGM1 cell
proliferation and viability in vitro using aMTT assay. In this setting,
5TGM1 cells were treated for 24 h with increasing concentrations
of MTM (ranging from 25 nM to 800 nM). As shown in Figure 1
A, treatment with MTM induced a dose-dependent decrease of
cell proliferation and the median inhibitory concentration (IC50)
was 600 nM. To determine whether the reduction in 5TGM1 cell
proliferation was accompanied by apoptosis induction, cells were
incubated with MTM or vehicle for 24 h and 48 h and early and
late apoptosis rates were assessed by flow cytometry using a double
annexin V/PI-staining (Figure 1 B). When cells were treated for
24 h with the drug, no effect on early apoptosis was observed.
However, a significant effect on late apoptosis and necrosis was
observed with high concentrations of MTM (p,0.01). After 48 h
of MTM treatment, a dose-dependent increase of late apoptosis/
necrosis rate was observed in each condition compared to the
control condition.
To determine whether MTM affects cell cycle progression in
5TGM1 cells, cells were treated for 24 h with 200 nM and
400 nM of MTM and the DNA was stained with propidium
iodide, followed by flow cytometry analysis. As shown in Figure 2
A, treatment of cells with 200 nM and 400 nM of MTM resulted
in a dose-dependent increase of the percentage of cells in G0/G1
phase (45% and 61%, respectively) when compared to the non-
treated cells (37%) (p,0,01). A decreased percentage of cell in the
S phase was also observed (56. % versus 49% and 32% for the
200 nM or 400 nM conditions, respectively) (p,0,01). Knowing
that MTM acts through inhibiting SP1 or c-Myc, we investigated
protein expression of these two transcription factors by Western
blot. These experiments showed a reduction of c-Myc protein
levels, while SP1 levels were unaffected (Figure 2 B). Since p53
signalling cascade is known to play a role in the cell cycle arrest in
response to cellular stress like DNA damage [26], p53 production
was investigated using Western blot. Following MTM treatment, a
distinct increase in p53 protein expression was observed (Figure 2
B). Moreover, to understand the molecular mechanisms underly-
ing the observed MTM-induced inhibition of cell growth [27], the
expression of several intracellular regulators of the cell cycle was
assessed by Western blot analysis (Figure 2 B). For this, 5TGM1
cells were treated for 24 h with 200 nM and 400 nM of MTM.
MTM exposure resulted in a significant reduction of the
expression of cell cycle regulatory proteins, cyclins D1, E,
CDK2, CDK4, CDK6 and c-Myc, particularly with 400 nM
treatment. Knowing that CDK4, CDK6 and also Cyclin E,
through activation of CDK2, are responsible for phosphorylation
of pRb, the effect of MTM on the expression of pRb was
investigated. MTM treatment caused a decrease of pRb
phosphorylation in 5TGM1 cells. Because p21 and p27 mediate
the p53-dependent G1 phase arrest in response to a variety of
stress stimuli, their protein expression was evaluated by Western
blot, showing an increase in their protein expression (Figure 2 B).
In summary, cell cycle arrest at the transition of G1 to S phase
seems mediated by a decreased expression of cell cycle inducers
(such as cyclins and cyclin-dependent kinases) but also by an
increased expression of inhibitors such as p21 and p27 (which are
under control of p53).
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Anti-angiogenic Effects of MTM in the Rat Aortic Ring
Assay and Secretion of Angiogenic Factors
Angiogenesis was first assessed in vitro by using the rat aortic ring
assay (Figure 3 A). Figure 3 C and 3 D show the mean number
of vessels in function of the distance to the ring. The addition of
medium conditioned by untreated 5TGM1 cells to the aortic ring
culture increased the development of microvessels compared to the
control condition (MCDB+DMEM) (p,0.01) (Figure 3 C).
Direct addition of MTM in the rat aortic ring assay showed no
effect on vascular outgrowth (Figure 3 C), indicating that the
observed effect was mediated through an effect on 5TGM1 cells.
When increasing concentrations of MTM were added (200 nM or
400 nM) to 5TGM1 cells before collection of conditioned
medium, this angiogenic response was inhibited (p,0.001)
(Figure 3 D).
As VEGF plays a crucial role in angiogenesis, the expression of
this protein was assessed by ELISA in the conditioned medium of
cultured myeloma cells (Figure 4). After MTM treatment
(200 nM and 400 nM), VEGF production was significantly
(p,0.01) decreased. To assess the expression of other cytokines
and to obtain a more global view of the effect of MTM on
angiogenesis, a cytokine array was performed on the conditioned
medium of treated (400 nM) and the non-treated 5TGM.1 cells
(Figure S1 A and B). A down-regulation of several pro-
angiogenic factors as well as an up-regulation of anti-angiogenic
factors was found following MTM treatment. Notably, among the
tested cytokines, serpin E1 and IP10 were both found to be up-
regulated in the treated conditioned medium (Figure S1 C). In
particular, the member of CXC sub-family IP10 is known to be
expressed by endothelial cells and to be a potent angiogenesis
inhibitor in vivo [28]. Considering its acknowledged role in
angiogenesis, IP10 expression was also evaluated by ELISA in
both cell lysates and conditioned medium (Figure 4). Following
MTM treatment (200 nM and 400 nM, respectively), IP10
secretion was significantly induced both in 5TGM.1 cell lysates
(p,0.01 for both concentrations) and conditioned medium
(p,0.01 for 200 nM; p,0.001 for 400 nM).
MTM Shows Distinct Anti-tumor and Anti-angiogenesis
Effects in vivo
Intraperitoneal treatment with MTM was well tolerated and did
not induce any weight loss (results not shown). The treatment of
mice with MTM decreased BM infiltration by 5TGM1 cells with
25% compared to vehicle treated 5TGM1 mice (p,0.05)
(Figure 5 A). Splenomegaly was also significantly reduced by
21% after chronic treatment of animals with MTM compared to
treatment with vehicle (p,0.05) (Figure 5 B).
Immunohistochemical staining of CD31 on BM sections of
5TGM1-inoculated mice and age- and sex-matched control mice,
demonstrated an increase of the microvessel development in the
5TGM1 injected mice (p,0.001) (Figure 6). MTM treatment
resulted in a decreased angiogenic response (p,0.01). Angiogen-
esis quantification is shown in Figure 6 D.
Direct Effect of MTM on BM Endothelial Cells
To assess the direct effect of MTM on murine bone marrow
endothelial cells, we used the immortalized BM endothelial cell
lines STR-4 and STR-10. In the MTT assay, increasing
concentrations of MTM (ranging from 100 nM to 800 nM)
resulted in a minor anti-proliferative effect in STR-4 cells, while
MTM inhibited STR-10 proliferation with an IC-50 of 200 nM
(shown in Figure 7 A). MTM inhibited both STR-4 and STR-10
cell migration in the Boyden Chamber assay. As shown in
Figure 7 B and Figure S2 C, treatment with 200 nM and
400 nM reduced migration with 1,25-fold (200 nM STR4), 1,74-
fold (400 nM STR4), 1,41-fold (200 nM STR10) and 1,66-fold
(400 nM STR10) compared to vehicle treated cells. To confirm
the anti-migratory effects of MTM, a wound healing assay using a
IBIDI culture insert was performed. As shown in Figure 7 C and
7 D, treatment with MTM induced a decrease of cell migration in
both cell lines (61% and 85% of wound closed after 48 h of
treatment with 200 nM of MTM for STR-4 and STR-10
respectively compared to total closure of control condition).
Results of this assay are also illustrated in Figure S2 A Capillary-
like sprout formation from spheroid cultures was only inhibited at
high concentrations (800 nM) of MTM in both STR-4 and STR-
10 endothelial cells. Lower concentrations of MTM (200 and
400 nM had only significant effect on STR-4 (Figure 7D and
Figure 1. MTM inhibits proliferation and induces apoptosis in 5TGM1 cells. A Effect of MTM on 5TGM1 cell proliferation and viability. Cells
were treated with various concentrations of MTM for 24 h and viability was assessed using an MTT assay. There was a dose dependent inhibition in
DNA synthesis observed with an IC50 of 600 nM B The induction of apoptosis was determined by FACS analysis. Cells were incubated during 24 h or
48 h with MTM (0 nM, 200 nM, 400 nM and 800 nM) and annexin V/PI stainings were performed. A representative picture of FACS analysis shows no
induction of apoptosis after 24 h and the presence of late apoptotic cells after 48 h of treatment.
doi:10.1371/journal.pone.0062818.g001
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Figure S2 B), while sprouting by STR-10 cells was unaffected at
these concentrations (Figure 7F).
Discussion
In the current study, we have evaluated the in vitro and in vivo
anti-myeloma effects of the known cytotoxic agent MTM. There
has been a renewed interest in this molecule since interactions of
this molecule with the SP1 pathway have been reported and
because of a newly described anti-angiogenic effect [10–12]. SP1
has earlier been described to modulate autocrine interleukin (IL)-6
secretion by MM cell lines, affecting their growth [29]. This
secretion is dependent on upstream activation of ERK (extracel-
lular signal-regulated mitogen-activated protein kinase), finally
resulting in SP1-induced IL-6 transcriptional activation, in turn
promoting cell growth. Addition of MTM results in decreased IL-6
production and myeloma cell growth, whereas the ERK inhibitor
U0126 strongly inhibits SP1 recruitment at the IL-6 promoter site
[29]. More recently, SP1 was described as an important
transcription factor in MM cells [30]. Indeed, the authors
described a high nuclear expression and activity of SP1, associated
with increased DNA binding and SP1-responsive promoter
activity. Addition of siRNA and shRNA for SP1 inhibited MM
Figure 2. MTM induces a dose-dependent increase of the percentage of cells in G0/G1 phase. A Cell cycle analysis of 5TGM1 cells treated
with 0, 200 or 400 nM of MTM. Cells were treated for 24 h with 200 nM and 400 nM of MTM and DNA was stained with propidium iodide, followed by
flow cytometry analysis. This treatment resulted in a dose-dependent increase of the percentage of cells in G0/G1 phase (45% and 61%, respectively)
when compared to the untreated cells (37%) (p,0,01). A decreased percentage of cells in the S phase was also observed (56% versus 49% and 32%
for the 200 nM and 400 nM conditions, respectively) (p,0,01). Percentages of cells in G1, S or G2 phases following MTM treatment are indicated on
the graph. B Protein expression of c-Myc, p21, p27, p53, cyclin D/CDK4 and cyclin E/CDK2, cdk6, phospho Rb and SP1 analyzed by Western blot
(duplicates, repeated 3 times). Protein loadings were normalized with b-actin. Data shown are representative of at least three independent
experiments. We observed an upregulation of p53, an inhibition of c-myc, while SP-1 remained stable. Downstream, p21 and p27 were upregulated,
while cyclin B, cyclin E, CDK2, CDK4, CDK6 were decreased, which finally resulted in decreased phosphorlyation of Rb.
doi:10.1371/journal.pone.0062818.g002
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cell growth and survival, while terameprocol, a molecule that
competes with SP1-DNA binding, inhibited in vitro and in vivo MM
growth [30].
In our MM model, MTM showed in vitro a direct anti-
proliferative effect with an IC50 of 600 nM, which is in range
with previous reports. MTM inhibited cell proliferation and
induced a distinct G0/S1 cell cycle arrest. In addition to the anti-
proliferative effects observed, MTM also induced cell death at
high concentration. Whereas proliferation and cell cycle progres-
sion were inhibited after 24 h, the effects of MTM on apoptosis
were only seen at a later time point (48 h) with cells in late
apoptotic/necrotic range.
Further investigations on proteins implicated in the control of
cell cycle progression from G1 to S phase showed a decrease of
protein expression of cyclin D1, cyclin D2, CDK2, CDK4 and
CDK6. Considering the fact that up-regulation of cyclins [3] and
phosphorylation of CDKs [31] are implicated in cell cycle
progression in MM, the observed decreased protein expression
of these proteins following MTM treatment can explain the cell
cycle arrest. Western blot did not show any decrease in SP1
protein level after MTM treatment. These results indicate that
either SP1 is not implicated in mediating the direct effects of
MTM or that MTM acts by inhibiting the binding of the SP1
transcription factor to the promoter site of different genes. In this
Figure 3. MTM reduced the myeloma-associated neo-vascularization in vitro in a rat aortic ring assay. A Representative
photomicrographs (scale 256) of aortic rings cultured for 9 days with MCDB+DMEM, VEGF, MTM 400 nM, or with conditioned medium (CM) by
cancer cells treated with MTM 0 nM, 200 nM or 400 nM. B A grid of concentric rings is automatically drawn by making successive dilations of the
aortic ring boundary. Microvessel distribution is defined as the number of microvessel intersections with this grid plotted as a function of the distance
from the ring. C and D represent the mean numbers of vessels depending of the distance to the ring for control (C) and MTM treatment (D). The
addition of medium conditioned by treated 5TGM1 cells to the aortic ring culture increased the development of microvessels compared to the
control condition (MCDB+DMEM) (p,0.01). This angiogenic response was inhibited (p,0.001) when increased concentrations of MTM (200 nM and
400 nM) were added to 5TGM1 cells before collection of conditioned medium.
doi:10.1371/journal.pone.0062818.g003
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Figure 4. MTM induces decreased VEGF and IP10 secretion. Levels of VEGF were determined in medium conditioned by 5TGM1 cell following
24 h of MTM treatment. Levels of IP10 were determined in both conditioned medium and cell lysate. Results were obtained using ELISA assays.
doi:10.1371/journal.pone.0062818.g004
Figure 5. MTM reduced BM colonisation by 5TGM1 (A) and splenomegaly (B). Tumour load was assessed by flow cytometry analysis of GFP
cells and spleen weight was measured. Starting the day after injection (day 1), a group of mice was treated intraperitonealy twice weekly with MTM or
vehicle (DMSO dissolved in PBS). At day 32, mice were sacrificed.
doi:10.1371/journal.pone.0062818.g005
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latter case however, one would expect a decreased protein level,
because SP1 can bind its own promoter and induce an
autonomous loop [32]. One of the downstream genes regulated
by SP1 is c-Myc that also controls transition from G1 to S phase
during cell cycle progression [11]. In contrast to SP1, we observed
a dose-dependent decrease in c-Myc protein production. These
results raise some doubts on the initial results of Gerlo et al.
showing a close relation between SP1 and IL-6 secretion in MM
cells by using MTM as a selective SP1 inhibitor [29]. The
decreased expression of IL-6 that was observed after MTM
treatment may be due to other pathways.
Earlier studies indicated that MTM is a strong activator of
endogenous p53 protein in human hepatoma cells [33]. Our
results confirm that p53 protein expression was up-regulated
following MTM treatment. These results are in line with earlier
results in gynaecologic cancer cell lines, where MTM increased the
p53 activity through the initial suppression of mdm2 promoter
activity, which resulted in increased expression levels of p53
downstream target genes (e.g. PUMA and p21), and induced G0/
G1 arrest and apoptosis [34].
In our model, a clear increase was seen in protein levels of
p21Cip1 indicating that the p53 pathway remained active and that
there was no inhibition of transcriptional activation of p21Cip1
promoter mediated by SP1. Taken together, our results suggest
that the anti-proliferative effects of MTM are mediated by an
inhibition of c-Myc and an activation of p53 resulting in decreased
expression of cyclins and cyclin-dependent kinases and over-
expression of cell-cycle regulatory proteins p27Kip1 and p21Cip1.
In addition to its direct effect on malignant cells, MTM may
inhibit angiogenesis in several ways. First, it can bind to the GC
boxes in the promoter sequences of key genes that regulate
angiogenesis and inhibits SP1-stimulated transcription of genes
such as VEGF/VEGFR, bFGF/bFGFR, EGF/EGFR, IGF/
IGFR, PDGF and others. Further, it has the ability to inhibit the
binding of SP1 to GC boxes in promoter sequence of SP1 itself,
thereby inhibiting the autocrine amplification loop for SP1
signalling. In xenograft models of human cancer, the group of
Keping Xie et al. demonstrated single agent anti-tumour activity in
a variety of xenograft models (carcinoid, gastric cancer and
pancreatic cancer cell lines) [35,36]. In addition, additive or
synergistic activity was demonstrated when combined with agents
targeting the VEGF pathway. The authors showed that treatment
with Bevacizumab, a monoclonal antibody that inhibits vascular
endothelial growth factor, increased the expression of SP1 and its
downstream molecule VEGF, which could be suppressed by
MTM [35]. Therefore, the authors suggested that neutralization of
VEGF function by Bevacizumab may up-regulate the expression
Figure 6. MTM decreased angiogenic response. CD31 immuno-staining on bone marrow sections of control mice (A) or 5TGM1 injected mice,
treated with the vehicle solution (B) or with MTM (C). Original magnification 10x. D Quantification of microvessel density (MVD) using the hot spot
technique. MVD was decreased in MTM-treated mice compared with the group treated with the vehicle solution.
doi:10.1371/journal.pone.0062818.g006
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of SP1 via a positive feedback loop. Resistance to this treatment
with increased VEGF expression could be overcome by MTM.
Herein, for the first time, we observed that MTM treatment
reduced angiogenesis both in vitro and in vivo in multiple myeloma.
We noticed that the decrease of angiogenesis was not the result of
exaggerated cell death or of a global down-regulation of pro-
angiogenic factors but was the consequence of the up-regulation of
anti-angiogenic factors. In this study, we raise different arguments
in favour of such an up-regulation of anti-angiogenic genes. First,
direct addition of MTM to rat aortic ring assays had no effect on
vascular outgrowth. Second, the effect was only seen when MTM
was added during incubation of 5TGM1 for preparing condi-
tioned medium. Third after 24 h there was no increase in
apoptosis or cell death as seen with flow cytometry for annexin V/
PIA or trypan blue staining. A final proof of this concept was
afforded by the cytokine array that showed a global down-
regulation of pro-angiogeneic proteins but up-regulation of anti-
angiogenic genes. Among them, IP10, a member of the CXC sub-
family known to be an inhibitor of angiogenesis in vivo, was found
to be highly up-regulated. Interestingly, the IP-10 promoter does
not contain a GC box and its expression does not seem to be
mediated by SP1 [37]. The 5-flanking promoter region of IP10
contains multiple regulatory elements, including two interferon-
stimulated responsive elements, two signal transducers and
activators of transcription, two CCAAT/enhancer-binding pro-
teins b (C/EBP-b), and two nuclear factor kB (NF-kB)-binding
sites [38]. Complementary studies on the BM endothelial cell lines
STR-4 and STR-10 showed a possible direct effect of MTM on
endothelial cells. Indeed, MTM showed distinct effects on
endothelial cell migration, while proliferation was less affected.
These results are in line with an earlier observation showing that
similar doses of MTM had no significant effect on apoptosis of
HUVEC cells but affected DNA synthesis (37% decrease for
300 nM MTM) [39]. Inhibition of proliferation and migration
resulted in decreased repopulation in the wound healing assay, but
significant effects in a spheroid sprouting assay could only be seen
at very high doses of MTM. Anti-angiogenic effects of other
chemotherapeutic agents have been described earlier [40,41].
Hence, we previously described an anti-myeloma and anti-
angiogenic activity of Plitidepsin, a cyclodepsipeptide originally
isolated from the Mediterranean tunicate Aplidium albicans, that is
currently under investigation in a phase III study in MM. [42] The
anti-angiogenic effect observed of MTM in this study is based on
an upregulation of anti-angiogenic factors (such as IP-10) and a
most likely effect on proliferation and migration of endothelial
cells.
Chronic intraperitoneal treatment with MTM also resulted in a
significant decrease of 5TGM1 cell invasion in the mice BM. As
myeloma cells accumulate into the spleen in this model,
splenomegaly was also reduced following MTM treatment. We
believe that the current results sustain the idea that neovascular-
isation is induced by the presence of myeloma cells and that the
observed decrease in angiogenesis probably contributes to the anti-
myeloma effects but this may not the sole explication. Indeed,
treatment of a xenograft myeloma model with the kinase inhibitor
dasatinib reduced myeloma-induced angiogenesis to basal levels,
but there was still tumour progression [43]. This indicates that
neo-vascularization is not required for final tumor development.
The observed effects in our model are thus probably due to both
anti-myeloma effects and anti-angiogenic effects. In spite of these
encouraging results, the use of MTM is limited due to its toxic side
effects and its small therapeutic range [44]. The introduction of
new analogues and other drug preparations, such as liposomal
Figure 7. MTM inhibits proliferation, migration and invasion of endothelial cell lines STR4 and STR10. Proliferation and viability was
assessed using an MTT assay. Wound healing assay and Boyden chamber assay were used to study migration. Cell sprouting was assessed using a
spheroid sprouting assay. Cells were treated with various concentrations of MTM during 24 h and 48 h. (A) Increasing concentrations of MTM
resulted in a minor anti-proliferative effect in STR-4 cells, while MTM inhibited STR-10 proliferation with an IC-50 of 200 nM. (B) MTM inhibited both
STR-4 and STR-10 cell migration in the Boyden Chamber assay. (C,D) Wound healing assay showed that adding 200 nM MTM decreased cell
repopulation by both cells lines. In the spheroid sprouting assay (E, F), treatment with 200 nM or 400 nM had only an effect on the STR4 cell line
whereas 800 nM of MTM caused an significant decrease in vessel sprouting by both cell lines.
doi:10.1371/journal.pone.0062818.g007
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formulations and its recent anti-angiogenic effects renew the
current interest in this molecule [14,45–47].
In conclusion, MTM treatment resulted in a clear anti-myeloma
activity, both in vitro and in vivo. MTM treatment resulted in a
significant effect against various endpoints of the multiple
myeloma disease, such as BM invasion, malignant cell prolifera-
tion, cell cycle progression and angiogenesis. Importantly, we have
highlighted that anti-angiogenic effects of the drug result from an
up-regulation of anti-angiogenic factors. Despite the toxic range
limitation of MTM, our results suggest that the use of MTM drug
analogs or liposomal formulations, or combination with other
therapeutic agents are worth considering for further preclinical
studies in MM disease.
Supporting Information
Figure S1 Proteome profiler mouse angiogenesis array.
Cytokine array was performed on conditioned medium of 24 h
non treated cell and treated cell with 400 nM of MTM. A
Representative cytokine array. The block arrows represent the
serpin E1 expression and the dotted arrow the IP10 expression. B
Diagram represents the mean signal intensity (AU) of the
expressed cytokines in treated (400 nM) and non treated (0 nM)
conditions. C Diagram represents the two major cytokines
modulated: serpin E1 and IP10.
(TIF)
Figure S2 Illustrations of migration assays and sprout-
ing assay. A Wound healing assay. BM endothelial cell line
STR-4 was in cultured in an Ibidi cell culture inserts that causes a
500 mm gap in the monoloyer. After incubation with RPMI-1640
with 10% FBS, this gap was completely repopolulated after 24 h
by migrating endothelial cells. Treatment with 200 nM MTM
abrogated this process resulting in a persistent opening. B.
Spheroid sprouting assay Spheroids consisting of endothelial
cells cultured in methylcellulose were moved in collagen gels and
endothelial cell out growth and capillary-like sprout formation was
followed. Addition of MTM reduced cell outgrowth and sprouting
formation compared to the control condition. These differences
were significant at 400 nM and 800 nM. C Boyden Chamber
assays. Representative photomicrographs of migrated STR-4
cells at 20x magnification. Both 200 and 400 nM MTM inhibited
endothelial cell migration to the lower chamber.
(TIF)
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